244 related articles for article (PubMed ID: 35470273)
1. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
[TBL] [Abstract][Full Text] [Related]
2. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
4. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
5. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
6. Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.
Gozzetti A; Pacelli P; Raspadori D; Bestoso E; Tocci D; Sicuranza A; Bocchia M
Rev Recent Clin Trials; 2022; 17(2):92-96. PubMed ID: 35578845
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
8. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
9. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
[TBL] [Abstract][Full Text] [Related]
10. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
[TBL] [Abstract][Full Text] [Related]
14. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
15. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
16. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
[TBL] [Abstract][Full Text] [Related]
17. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Mohan M; Kendrick S; Szabo A; Yarlagadda N; Atwal D; Pandey Y; Roy A; Parikh R; Lopez J; Thanendrarajan S; Schinke C; Alapat D; Sawyer J; Tian E; Tricot G; van Rhee F; Zangari M
Blood Adv; 2022 Feb; 6(3):808-817. PubMed ID: 34807986
[TBL] [Abstract][Full Text] [Related]
19. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
20. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
[No Abstract] [Full Text] [Related]
[Next] [New Search]
